PharmaCyte Biotech Inc (PMCB)

[1234jklm]

Mellingen cells are superior to Islet and beta cells

Islet and beta cells are hard to acquire and famously difficult to keep alive in the body. Mellingen cells are far superior.


Viacyte has a two year delay now because of problems encountered in its clinical trials.

Pcmb has an exclusive license to the melingen cells.

Pcmb has a superior product and it will not be a surprise if novo or j&j are interested in it.

Wonderful to know that there is such belief in encapsulation as a treatment for diabetes. And so much funding available.

Puts to rest all the posts that say this twenty year old technology is not valid or wanted by large pharma. Clearly all just noise when an organization like this is so committed to it.

An exciting next few weeks for sure.